Dr. Graff on Genomic Risk Prediction in HR+/HER2- Breast Cancer

Stephanie L. Graff, MD, director of the Breast Program at the Sarah Cannon Cancer Institute of HCA Midwest Health and associate director of the Breast Cancer Research Program at Sarah Cannon Research Institute, discusses genomic risk prediction in patients with hormone receptor (HR)–positive, HER2-negative breast cancer.